Comparative assessment of primary and paraneoplastic gout in lung cancer
DOI:
https://doi.org/10.14739/2310-1210.2018.6.146579Keywords:
gout, lung cancer, paraneoplastic syndromeAbstract
Introduction. Lung cancer (LС) is the most common cause of the so-called paraneoplastic syndrome (PNPS) development, caused by the complex immunoinflammatory, degenerative and vascular distant changes. The risk of LC development is increased in patients with gout which proves the connection between violations of purine metabolism and carcinogenesis. Paraneoplastic (neoplastic) gout is one of the relatively frequent manifestations of LC, but such a relationship of the diseases requires further study.
The objective of the study: to compare the clinical and laboratory course of primary gout and disease in the LC patients compared with the tumor process clinical course in the other signs of PNPS presence and to identify risk factors.
Materials and methods. 113 patients with gout (97 men and 16 women aged 33 to 79 years) were observed. They were divided into two groups: the first group consisted of 54 patients with primary gout and the second group consisted of 59 patients with paraneoplastic variant of LC. Whereas in the 1st group the ratio of men and women was 26:1, in the 2nd – only 3: 1, and the average age was 50 and 59 years, respectively. The clinical course of gout and tumor process in the 2nd (main) group was compared with that in 199 LC patients with PNPS (comparison group), which was diagnosed in 15.5 % of LC observations. Purine metabolism was assessed by blood levels of uric acid and oxypurinol, their renal clearance, serum activity of xanthine oxidase, xanthine deaminase, adenosine deaminase, and 5-nucleotidase.
Results. Paraneoplastic (neoplastic) gout develops in 3.5 % of the LC patients and in 22.9 % of those with PNPS. It differs from the primary (idiopathic) gout by the greater frequency of the disease development in women, the hand joints involvement and the metabolic type of hyperuricemia, but less often observed urolithiasis, peripheral tophi, chronic form of arthritis and the absence of renal type of purine metabolism impairment. Patients with tumorous gout differ from other LC patients with PNPS by the absence of bilateral and median lobe localization of the lung process, but relatively frequent occurrence of Pancoast tumor, high levels of uric acid and xanthine oxidase in the blood. The development of paraneoplastic gout depends on the clinical course of the LC (tumor invasion into the thoracic wall and pericardium, the number of distant organs metastasis) and the power of chemotherapy, the use of alkylating antineoplastic agents and alkaloids. Treatment-associated myelodepression, radiation pneumofibrosis and acute thrombophlebitis development depends on paraneoplastic gout. The presence of gout does not worsen the survival of LC patients with PNPS. LC patients with hyperuricemia (> 420 μmol / l in men and > 360 μmol / L in women) should be prescribed with xanthine oxidase inhibitor - allopurinol in the complex of therapeutic measures.
Conclusions. Paraneoplastic gout is a frequent PNPS manifestation in LC, its course has peculiarities compared with the primary gout and is closely related to the tumor process character and the power of chemotherapy, it can determine the complications development in the course of therapeutic interventions. The data presented in the study require further comparative analysis of the other signs of PNPS, comparison of tumor and idiopathic variants of the musculoskeletal system lesion, cutaneous vasculitis and autoimmune systemic syndromes, which might assist in developing of the additional prognostic criteria for the tumor process clinical course, increasing the efficiency of therapy and its control quality.
References
Roddy, E., & Choi, H. K. (2014) Epidemiology of gout. Rheum Dis Clin North Am, 40(2), 155–75. doi: 10.1016/j.rdc.2014.01.001.
Kiadaliri, A. A., Uhlig, T., & Englund M. (2018) Burden of gout in the Nordic region, 1990–2015: findings from the Global Burden of Disease Study 2015. Scand J Rheumatol, 47(5), 410–417. doi: 10.1080/03009742.2017.1405461.
Kuo, C. F., Grainge, M. J., See, L. C., Yu, K. H., Luo, S. F., Zhang, W., & Doherty, M. (2016) Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther, 17, 13. doi: 10.1186/s13075-015-0522-8.
Grаdalska-Lampart, M., Karczmarek-Borowska, B., & Radziszewska, A.U. (2015) Lung cancer in Podkarpackie region in the years 2002–2011. Pneumonol Alergol Pol, 83(2), 109–19 .doi: 10.5603/PiAP.2015.0018.
Latimer, K. M. (2018) Lung cancer: clinical presentation and diagnosis. FP Essent, 464(1), 23–6.
Qu, H. M., Bai, Y. N., Cheng, N., Dai, M., Zheng, T. Z., Wang, D., et al. (2015) Trend analysis of cancer mortality in the jinchang cohort, China, 2001–2010. Biomed Environ Sci, 28(5), 364-9. doi: 10.3967/bes2015.050.
Wilkins, C. M., Johnson, V. L., Fargason, R. E., & Birur, B. (2017) Psychosis as a sequelae of paraneoplastic syndrome in small-cell lung carcinoma: A psycho-neuroendocrine interface. Clin Schizophr Relat Psychoses, doi: 10.3371/CSRP.CWVJ.111717.
Hébant, B., Miret, N., Berthelot, L., Jaafar, M., Maltête, D., & Lefaucheur, R. (2016) Generalized pruritus preceding paraneoplastic neuropathy. J Clin Neurosci, 26, 156–7. doi: 10.1016/j.jocn.2015.09.015.
Ramírez-Bellver, J. L., Macías, E., Bernárdez, C., López-Robles, J., Vegas-Sánchez, M. D., Díaz-Recuero, J. L., et al. (2017) Anti-NXP2-positive paraneoplastic dermatomyositis with histopathologic changes confined to the acrosyringia. Am J Dermatopathol, 39(1), e3–e7. doi: 10.1097/DAD.0000000000000694.
Durieux, V., Coureau, M., Meert, A. P., Berghmans, T., & Sculier, J. P. (2017) Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature. Lung Cancer, 106, 102–9. doi: 10.1016/j.lungcan.2017.01.015.
Wang, W., Xu, D., Wang, B., Yan, S., Wang, X., Yin, Y., et al. (2015) Increased risk of cancer in relation to gout: a review of three prospective cohort studies with 50,358 subjects. Mediators Inflamm. 2, 1–6. doi: 10.1155/2015/680853.
Coburn, B. W., Michaud, K., Bergman, D. A., & Mikuls, T. R. (2018) Allopurinol dose escalation and mortality among patients with gout: a national propensity-matched cohort study. Arthritis Rheumatol, 70(8), 1298–1307. doi: 10.1002/art.40486.
Tu, H., Wen, C. P., Tsai, S. P., Chow, W. H., Wen, C., Ye, Y., et al. (2018) Cancer risk associated with chronic diseases and disease markers: prospective cohort study. BMJ, 360, k134. doi: 10.1136/bmj.k134.
Kuo, C. F., Luo, S. F., See, L. C., Chou, I. J., Fang, Y. F., & Yu, K. H. (2012) Increased risk of cancer among gout patients: a nationwide population study. Joint Bone Spine, 79(4), 375–8. doi: 10.1016/j.jbspin.2011.09.011.
Boffetta, P., Nordenvall, C., Nyrén, O., & Ye, W. (2012) A prospective study of gout and cancer. Eur J Cancer Prev, 18(2), 127–32. doi: 10.1097/CEJ.0b013e328313631a.
Kanaji, N., Watanabe, N., Kita, N., Bandoh, S., Tadokoro, A., Ishii, T., et al. (2014) Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol, 5(3), 197–223. doi: 10.5306/wjco.v5.i3.197.
Hande, K. R., Noone, S. M., & Stone, W. J. (1994) Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med, 76(1), 47–56.
Paraschiv, B., Diaconu, C. C., Toma, C. L., & Bogdan, M. A. (2015) Paraneoplastic syndromes: the way to an early diagnosis of lung cancer. Pneumologia, 64(2),14 –9.
Miret, M., Horváth-Puhó, E., Déruaz-Luyet, A., Sørensen, H. T., & Ehrenstein, V. (2017) Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study. PLoS One, 12(8), 0181564. doi: 10.1371/journal.pone.0181564.
Pileckyte, M., Baliūnaite, R., & Tamulaitiene, V. (2018) Paraneoplastic rheumatic syndromes. Medicina, 39(5), 443–7.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)